Skip to main content
Journal cover image

Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass.

Publication ,  Journal Article
Li, JS; Sanders, SP; Perry, AE; Stinnett, SS; Jaggers, J; Bokesch, P; Reynolds, L; Nassar, R; Anderson, PAW
Published in: Am Heart J
January 2004

BACKGROUND: Increase in vascular permeability and multiorgan dysfunction after cardiopulmonary bypass (CPB) are barriers to successful cardiac surgery in infants. Complement inhibition with TP10, a C3/C5 convertase inhibitor (AVANT Immunotherapeutics, Needham, Mass), blunts post-CPB organ dysfunction in the neonatal pig. Methods and results The pharmacokinetics and safety of TP10 in infants (age <1 year, n = 15) undergoing CPB were examined in a phase I/II open-label prospective trial. TP10 (10 mg/kg) was given intravenously before CPB and also added (10 mg/100 mL prime volume) to the CPB circuit. TP10 plasma levels correlated with C3a levels and measures of clinical course. All infants survived. No adverse events were attributed to TP10. TP10 plasma concentration fell to < or =60 microg/mL 12 hours after CPB. A 2-compartment model was fit to the TP10 blood levels as a function of time. Based on this model, an initial dose of 10 mg/kg over 0.5 hours followed by 10 mg/kg over 23.5 hours is the most appropriate for maintaining TP10 concentration between 100 microg/mL and 160 microg/mL for 24 hours after CPB. C3a was lower 12 hours after CPB than before CPB and still lower 24 hours after CPB. TP10 concentration was inversely correlated with the 12-hour post-CPB to pre-CPB ratio of C3a (Spearman rho -0.76, P = -.016), and with total (rho -0.56, P =.047) and net (rho -0.85, P =.0016) fluid and blood product administration/kg >24 hours after CPB. CONCLUSIONS: TP10 administration to infants appears safe. Pharmacokinetic analysis generated an optimal dosing strategy to achieve effective TP10 levels for 24 hours after CPB. In the infant, TP10 appears to decrease CPB-induced complement activation and protect vascular function. These results support a phase III trial of TP10 in infants requiring CPB.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

January 2004

Volume

147

Issue

1

Start / End Page

173 / 180

Location

United States

Related Subject Headings

  • Syndrome
  • Statistics, Nonparametric
  • Receptors, Complement
  • Prospective Studies
  • Male
  • Infant
  • Humans
  • Heart Defects, Congenital
  • Female
  • Complement Inactivator Proteins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, J. S., Sanders, S. P., Perry, A. E., Stinnett, S. S., Jaggers, J., Bokesch, P., … Anderson, P. A. W. (2004). Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J, 147(1), 173–180. https://doi.org/10.1016/j.ahj.2003.07.004
Li, Jennifer S., Stephen P. Sanders, April E. Perry, Sandra S. Stinnett, James Jaggers, Paula Bokesch, Laurie Reynolds, Rashid Nassar, and Page A. W. Anderson. “Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass.Am Heart J 147, no. 1 (January 2004): 173–80. https://doi.org/10.1016/j.ahj.2003.07.004.
Li JS, Sanders SP, Perry AE, Stinnett SS, Jaggers J, Bokesch P, et al. Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J. 2004 Jan;147(1):173–80.
Li, Jennifer S., et al. “Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass.Am Heart J, vol. 147, no. 1, Jan. 2004, pp. 173–80. Pubmed, doi:10.1016/j.ahj.2003.07.004.
Li JS, Sanders SP, Perry AE, Stinnett SS, Jaggers J, Bokesch P, Reynolds L, Nassar R, Anderson PAW. Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J. 2004 Jan;147(1):173–180.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

January 2004

Volume

147

Issue

1

Start / End Page

173 / 180

Location

United States

Related Subject Headings

  • Syndrome
  • Statistics, Nonparametric
  • Receptors, Complement
  • Prospective Studies
  • Male
  • Infant
  • Humans
  • Heart Defects, Congenital
  • Female
  • Complement Inactivator Proteins